In the news
What Happened To My Mental Health After I Took Acid
Article in Refinery29 on the potential of psychedelics in mental health, including an interview with our co-founder, Ekaterina.
What it’s like to trip on psilocybin for a scientific research study
Article in New Scientist by Sam Wong, writing about his experience of taking psilocybin as a participant in our study of healthy volunteers at King’s College London.
Shroom-Therapy Startup Edges Toward FDA Approval
Feature in Bloomberg Businessweek on COMPASS, including interview with our co-founders, Ekaterina and George.
In a key step for psychedelic research, magic mushroom compound clears first clinical safety hurdle
Endpoints News article on the results of our psilocybin study in healthy volunteers.
Psilocybin: Four Important Takeaways from a Clinical Trial
Article in Psychology Today on our “pioneering research” conducted at King’s College London.
Interview with our CEO and Co-Founder, George Goldsmith on BioBoss podcast
"The most creative thing in the world for me is just how does an idea get transformed by the people who collect around it." - George Goldsmith, Co-Founder and CEO of Compass Pathways
Magic mushroom treatment for depression one step closer after psilocybin passes safety test
Further coverage of our psilocybin study conducted by King’s College London, published in Newsweek
Magic mushrooms offer hope for depression
Article in The Times on results from our psilocybin trial in healthy volunteers
Magic mushroom medicine passes first clinical safety trial
Front page article in the Financial Times reporting on results from COMPASS trial of psilocybin.
COMPASS Pathways and King’s College London announce results from psilocybin study in healthy volunteers
COMP360 (psilocybin) was well tolerated in healthy volunteers
Psilocybin: Four Takeaways from a Clinical Trial
Article in Psychology Today on our "pioneering research" conducted at King's College London.
In a key step for psychedelic research, magic mushroom compound clears first clinical safety hurdle
Endpoints News article on the results of our psilocybin study in healthy volunteers
For-profit psychedelics and access for all: a conversation with Ronan Levy of Field Trip Psychedelics
Interview with Ronan Levy in Psychedelic Times, discussing for-profit psychedelics in mental healthcare and access to them by historically underserved communities
Investors hope psychedelics are the new cannabis. Are they high?
The Economist piece about investment in psychedelic research for mental health, featuring Ekaterina Malievskaia.
Could psychedelic drugs be a cure for depression?
Video on Today about whether psychedelics couldÂ help people suffering from severe depression
Down the rabbit hole: treating depression with psychedelic drugs
Article about how psychedelics could be used to treat depression, featuring COMPASS Chief Innovation Officer and Co-founder, Ekaterina Malievskaia
Can magic mushrooms really cure depression?
Article in The Telegraph about whether magic mushrooms could be a potential cure for depression
Psychedelic drug research breaks out of deep freeze as researchers head for the clinic with ambitious trial plans
Endpoint News article about the changes in how psychedelic drugs are viewed by clinicians and how they could treat psychiatric disorders
Johns Hopkins opens new Center for Psychedelic Research
An article from the New York Times about the new Center for Psychedelic Research at John Hopkins
Psychedelic drugs draw some investor attention – and much skepticism
An article from The Wall Street Journal about how a few entrepreneurs and investors see opportunity for novel mental health treatments
Psilocybin is headed for the mainstream — it’s bringing the problems of big pharma with it
Medium looks at how the psychedelic community is torn overÂ the growing interest in developing medical versions of a drug that may even help treatment-resistant depression
Psychedelic medicine is coming. The law isn’t ready
Article by Scientific American about how the resurgence of psychedelic research has produced its first FDA-approved treatment.
Podcast: An interview with Lars Wilde, COMPASS Pathways
COMPASS Pathways Co-founder, Lars Wilde, talks about fundraising on the Worldwide Clinical Trials podcast
Are psychedelics going mainstream?
J. Walter Thompson Intelligence piece on how psychedelic drugs are gaining mainstream recognition, from treating depression to achieving a deeper understanding of consciousness.
First pot, then magic mushrooms? Decriminalization is spreading
Bloomberg explores that, as cannabis legalisation spreads across the globe, another mind-altering drug is trying to follow in its tracks: magic mushrooms.
Could magic mushrooms ever replace today’s anti-depressants?
Healthline article on whether psilocybin could replace anti-depressant medications.
Prevention: the new holy grail of treating mental illness
Article from the Guardian about how investing in keeping people well could save many lives and a lot of money
‘They broke my mental shackles’: could magic mushrooms be the answer to depression?
Article from The Guardian quoting Co-founder Ekaterina Malievskaia about how psilocybin could work as a reliable treatment for depression
Magic mushrooms, illegal in most places, may have therapeutic uses
Article by The Economist about whether the active ingredient in magic mushrooms, psilocybin, offers hope in treating depression
The magic of psilocybin in treatment of depression
Feature piece on COMPASS Pathways in Spring edition of Pharmafile
Michael Pollan: not so fast on psychedelic mushrooms
Opinion piece by Michael Pollan on the legalisation of magic mushrooms, for The New York Times
Are psychedelic drugs the cure for depression?
Men’s Health article about whether psychedelic drugs could be a powerful and viable mental health tool
Psychedelics: mind-enhancing methods to well-being
Panel discussion at Milken Global Conference, featuring researchers, practitioners, and investors on the use of psychedelics in mental health research
Tim Ferriss just helped launch the world’s first research center dedicated to turning psychedelics into medicines
Business Insider article about the world’s first research centre dedicated to turning psychedelics into medicines, where scientists will explore the drugs’ potential to treat mental illnesses like depression
Psychedelic therapy for depression
Article by The Naked Scientists about FDA breakthrough designation for psilocybin therapy
Will MDMA-assisted psychotherapy be covered by health insurance?
Article by Psymposia Magazine quoting Ekaterina Malievskaia on whether MDMA-assisted psychotherapy will be covered by health insurance
CBC Radio: psychedelic drugs and the future of psychiatry
Canadian Broadcasting Corporation programme about psychedelics and mental health, featuring George Goldsmith.
Building a Psychedelic Enterprise
Video of an event hosted by UCL Society for the Application of Psychedelics and LSESU Neuroscience Society. COMPASS founders talk about patients, profits, patents and psychedelics.
Psychedelic Times: Interview with Rick Doblin, Founder and Executive Director, MAPS
Psychedelic Times interviews Rick Doblin, founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), about psychedelics and capitalism.
Psilocybin Could Be Legal for Therapy by 2021
"For the first time in U.S. history, a psychedelic drug is on the fast track to getting approved for treating depression by the federal government", Rolling Stone
FDA “Breakthrough” Ruling on Magic Mushrooms, Explained by Scientists
“This is an important advance in bringing these compounds out of the dark ages” – Inverse explains the recent FDA breakthrough therapy designation obtained by COMPASS and what this means.
Company of the Month: COMPASS Pathways
MedCity names COMPASS as their Company of the Month.
Psychedelic Psilocybin Therapy for Depression Granted Breakthrough Therapy Status by FDA
Article from New Atlas covering COMPASS’ breakthrough therapy designation, awarded by the FDA, and other psychedelic research.
The renaissance of psilocybin as a viable treatment option
Article from pharmaceutical-technology.com listing current clinical trials involving psilocybin
FDA Approves Psychedelic Magic Mushrooms
The Food and Drug Administration has approved the use of the psychedelic ingredient in magic mushrooms for a drug trial for treatment-resistant depression.
‘Reluctant Psychonaut’ Michael Pollan Embraces The ‘New Science’ Of Psychedelics
National Public Radio Fresh Air podcast with Michael Pollan on his new book “How to Change Your Mind”.
Depression – The Psychedelic Cure?
Rob Reid interviews COMPASS founders Katya Malievskaia and George Goldsmith for his After On podcast. They discuss the motivations behind COMPASS as well as the clinical history of psychedelics.
My Adventures With The Trip Doctors
The researchers and renegades are bringing psychedelic drugs into the mental health mainstream. Read more about this feature article in the New York Times by Michael Pollan on psychedelic therapy.
Might LSD Be Good For You?
Many psychedelic drugs are non-addictive, and can be helpful in treating all sorts of psychological conditions, argues Michael Pollan. Sam Leith discusses and reviews “How to Change Your Mind: The New Science of Psychedelics” by Michael Pollan.
Magic Mushrooms May Treat Depression
A trial will assess whether psilocybin, the active ingredient in magic mushrooms, can help. This article is from The Sunday Times about COMPASS Pathways’ trial for treatment-resistant depression.
Mushrooms emerge from underground
“Magic mushrooms show promise to treat depression and anxiety–and major academic institutions and Silicon Valley are stepping up research and investment. The wellness travel space, in very creative ways, is moving from experiential to truly emotional and transformative travel”
Peter Thiel’s Bet on Magic Mushrooms
“High-profile Silicon Valley investor Peter Thiel made a bet last year on a company with an unusual idea for treating depression: psychedelics.”
Mind Menders: How Psychedelic Drugs Rebuild Broken Brains
The healing powers of illegal drugs like MDMA and psilocybin are finally living up to the hype – and they are already transforming our view of mental illness.
‘Magic mushrooms’ take a trip into clinical trials
Hundreds of Europeans with depression will soon have the chance to turn on, tune in and drop out of existing drug treatments, in the largest clinical trial ever launched to assess the medicinal effects of a psychoactive substance
Can magic mushrooms provide lasting peace?
Psilocybin has been illegal in the United States for more than 40 years. But Mr. Mihai, who had just finished treatment for Stage 3 Hodgkin’s lymphoma, was participating in a study looking at whether the drug can reduce anxiety and depression in cancer patients
Just one dose of this psychedelic drug can ease anxiety
In two new studies released simultaneously by researchers at New York University and Johns Hopkins, doctors reveal that a single dose of psilocybin—a compound from magic mushrooms—can ease anxiety and depression for up to six months
Magic mushroom drug helps people with cancer face death
Can a psychedelic trip change the way people with life-threatening cancer face death? Results from two clinical trials suggest so, as reported in New Scientist
‘Magic mushroom’ drug lifts depression in first human trial
An Imperial College London proof of concept study on psilocybin for treatment resistant depression has interesting results. The hallucinogenic drug derived from magic mushrooms could be useful in treating depression, the first safety study of this approach has concluded.
How magic mushrooms could treat depression
Treating depression is a major challenge, since among the millions of people affected worldwide, only one in five tends to respond well to antidepressants. Now, there’s a new, albeit controversial, approach being considered by scientists.
One Writer’s Trip
A video of journalist Michael Pollan’s autobiographical talk on the altered states of consciousness that certain plants and fungi allow us to achieve.
Real trip treatment
Research into psychedelics, shut down for decades, is now yielding exciting results. In this article from The New Yorker, Michael Pollan presents a considered overview of psychedelic-assisted therapy, its history and its potential benefit to patients
‘Magic mushrooms’ and the healing trip
The way in which we commonly perceive so-called magic mushrooms—as the means to youthful psychedelic adventure—is undergoing a radical transformation.
Can mushrooms treat depression?
"The brains on psilocybin showed radically different connectivity patterns between cortical regions (the parts thought to play an important role in consciousness). "
Hallucinogens have doctors tuning in again
Scientists are taking a new look at hallucinogens, which became taboo among regulators after enthusiasts like Timothy Leary promoted them in the 1960s with the slogan “Turn on, tune in, drop out.”